SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Scientists organize millions of proteins by shape, as predicted by AI, revealing 700,000 new families and some shapes unique ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
SIMI VALLEY, California.—The White House has greenlit a plan to design and build a frigate domestically as part of its proposed “Golden Fleet,” Navy Secretary John Phelan announced at the Reagan ...
The Trump administration offered states a deal: pledge to enact White House-favored policies for a chance to win a bigger share of the $50 billion aimed at transforming the nation’s struggling rural ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback